Neurogene Q2 net loss $18.5M; NGN-401 gets RMAT and START FDA designations

Neurogene Inc.

2024-Q2 EPS reported -$2.09 revenue$925,000

Cash and equivalents $153.9M as of June 30, 2024; expected to fund operations into 2H 2026.
Net loss $18.5M in Q2 2024 vs $11.9M in Q2 2023; R&D expenses rose to $15.7M from $10.3M.
NGN-401 for Rett syndrome received RMAT designation and was selected for FDA START Pilot Program.
First patient dosed in high-dose Cohort 2; interim efficacy data from Cohort 1 expected Q4 2024.
Enrollment complete in NGN-101 for CLN5 Batten disease; data and regulatory update in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.